Innoviva
Overview
Innoviva is a biopharmaceutical company that manages a portfolio of royalties from healthcare assets and invests in the development and commercialization of new medicines in areas of unmet need.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Beacon Biosignals | Apr 2026 | Series B | Co-investor |
| Gate Neurosciences | May 2025 | M&A | Lead |
| InCarda Therapeutics | Jun 2022 | Series D | Co-investor |
| Nanolive SA | Sep 2022 | Series C | Lead |
| ImaginAb | Sep 2023 | Series C Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Innoviva based?
Innoviva is headquartered in Burlingame, California, United States.
When was Innoviva founded?
Innoviva was founded in 1996.
How many portfolio companies does Innoviva have?
Innoviva has 5 portfolio companies in Caplight's dataset.
What are some companies in Innoviva's portfolio?
Portfolio companies visible on Caplight include Beacon Biosignals, Gate Neurosciences, InCarda Therapeutics, Nanolive SA, ImaginAb.
What was Innoviva's most recent investment shown here?
Innoviva's most recent investment in this portfolio sample was in Beacon Biosignals in 2026.
What sectors does Innoviva focus on?
Innoviva focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Innoviva focus on?
Innoviva typically invests at the Mid stage.
What is Innoviva's AUM?
Innoviva's assets under management are estimated between $449.3M and $501.5M.